No products in the cart.
ITGAL: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It’s the GeneMedi’s summary page for Target/Biomarker Introduction of ITGAL. The page also collects GeneMedi’s different modalities and formats products for ITGAL in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the ITGAL target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
ITGAL encodes the integrin alpha L chain. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. This I-domain containing alpha integrin combines with the beta 2 chain (ITGB2) to form the integrin lymphocyte function-associated antigen-1 (LFA-1), which is expressed on all leukocytes. LFA-1 plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
|
Target ID |
GM-T35640
|
|
Target Name |
ITGAL
|
|
Gene ID |
3683
|
|
Gene Official Name |
ITGAL
|
|
Gene Alias |
CD11A, LFA-1, LFA1A
|
|
Protein Sub-location |
Transmembrane Protein
|
|
Category |
Therapeutics Target, INN Index
|
Pre-made ITGAL-specific INN-index biosimilar (antibody&conjugates)-odulimomab, rovelizumab, Efalizumab
Anti-ITGAL therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Filters
Sort results
Reset
Apply
Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Order |
|---|---|---|---|---|---|---|
Pre-Made Efalizumab biosimilar, Whole mAb, Anti-ITGAL Antibody: Anti-CD11A/LFA-1/LFA1A therapeutic antibody |
Efalizumab |
NA |
ITGAL |
Whole mAb |
||
Pre-Made Odulimomab Biosimilar, Fab Fusion, Anti-Itgal Antibody: Anti-CD11A/LFA-1/LFA1A therapeutic antibody |
odulimomab |
NA |
ITGAL |
Fab Fusion |
||
Pre-Made Rovelizumab Biosimilar, Bispecific, Anti-Itgal;Itgb2 Antibody: Anti-CD11A/LFA-1/LFA1A;CD18/LAD/LCAMB/LFA-1/MAC-1/MF17/MFI7 therapeutic antibody |
rovelizumab |
NA |
ITGAL,ITGB2 |
Bispecific |
Anti-ITAL/ ITGAL/ CD11A antibody for FACS & in-vivo assay| GMab
Pre-made anti-ITGAL benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-ITGAL mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Filters
Sort results
Reset
Apply
Cat No. | Antibody Name | Format | Classified by tag | Order
|
|---|---|---|---|---|
Anti-ITGAL monoclonal antibody |
mab |
FACS/Biofunctional Antibody, Therapeutics Target antibody |
